Mobile-health Network Solutions [MaNaDr] to Offer GLP-1 Injectables for Medical Weight Loss from USD10/Day

▴ [MaNaDr]
Many weight management solutions available today ultimately fail – partly because patients do not receive the help they need, when they need it.

SINGAPORE, June 20, 2024 - (NewMediaWire) - Mobile-health Network Solutions ['MaNaDr'] (Nasdaq: MNDR), a leading Asia-Pacific telehealth provider, has announced updated pricing for its medical weight management program, improving the affordability and accessibility of GLP-1 (glucagon-like peptide-1) receptor agonist medications in the Asia-Pacific (APAC) region.

The program, designed to stem the growing prevalence of obesity in Singapore and across the APAC region, is believed to be among the most competitively priced in the region. As a result, MaNaDr expects the program will have a significant adoption rate and provide meaningful incremental revenue starting in the third quarter of the current calendar year.

https://tinyurl.com/393w6z9z
https://tinyurl.com/393w6z9z 


"Leveraging our strong partnerships, we offer a range of GLP-1 medications directly sourced from the leading pharmaceutical innovators," said Ms. Law Pei Bei, Chief Business Officer. "This means patients have access to the original, brand-name GLP-1 injections, ensuring the highest quality and proven results.

"We've negotiated competitive pricing with these leading pharmaceutical manufacturers, allowing us to offer original GLP-1 medications at pricing starting at less than US$10 per day. This low pricing makes these treatments a realistic option for most weight management patients."

Co-CEO Dr. Siaw Tung Yeng, PBM, Senior Consultant Family Physician, added, "Telehealth consultations create a safe and comfortable environment for weight management discussions. This is especially beneficial for individuals who may experience shyness, social anxiety, or fear in a traditional setting. Telehealth empowers these patients to openly discuss their weight loss goals and challenges, fostering a supportive foundation for their journey."

Marketed with the tagline, "It's Okay to be Not Okay," the MaNaDr program is among the few of its kind in the APAC region to offer a one-stop source for patients' weight management needs.

Services provided include:

Medical Intervention. Patients can consult with doctors for personalized medical advice, including the suitability of using GLP-1 medications such as Semaglutide (brand names Wegovy and Rybelsus), Liraglutide (Saxenda), Dulaglutide (Trucility), or other prescription weight loss medications.

Mental/Emotional Support. Patients receive ongoing mental and emotional support from a dedicated personal care consultant and coach, who will set achievable goals, guide them through challenges, and celebrate their successes.

Nutritional Guidance. Patients can work with registered dietitians to develop a personalized, sustainable eating plan.

Fitness Expertise. Patients can consult with certified exercise instructors to create an exercise program that fits their needs and preferences.

24/7 Availability. Patients can contact a member of their healthcare team to discuss immediate concerns around the clock.

Data-Driven Tracking. Patients can track their progress with a user-friendly personal lifestyle diary that monitors meals, physical activity, and body measurements.

Community Forum. The in-app forum provides an additional layer of peer support, offering anonymity for individuals hesitant to share openly in a traditional group setting. 

Effortless Refills. Patients can refill their prescriptions quickly and easily within the MaNaDr app.

In-Clinic Option. Patients preferring in-person visits may schedule them and receive comprehensive physical evaluations.

"Many weight management solutions available today ultimately fail – partly because patients do not receive the help they need, when they need it," said MaNaDr co-CEO Dr. Rachel Teoh Pui Pui, PBM, Family Physician. "Our program addresses these challenges by prioritizing the three elements we believe are essential to successful weight loss: effective prescription medications, 24/7 mental health support, and personalized nutritional and fitness guidance. 

"Several recent studies demonstrate that GLP-1 medications like Saxenda can help most patients lose five to ten percent of their body weight within a reasonable period of time," stated Dr. Teoh. "Should patients experience side effects from using such medications, we will consider offering other medications, both prescription and over-the-counter, that will best help patients achieve a safe and successful outcome of their weight management goals."

Equally important, she added, is the availability of professional mental health support for weight management patients. "Often underestimated, and even overlooked, is the fear, isolation, cravings, and shame experienced by many patients with weight management issues. We address these needs by making certain that patients have a dedicated personal care consultant and coach who is thoroughly familiar with a patient's needs, and by making a professional available to consult with patients on a 24/7 basis. No patient in our program will ever have their needs ignored when they need help."

Dr. Teoh said the MaNaDr weight management program tailors a specific nutritional and fitness program for each patient based on their realistic needs and abilities. "Patients can follow nutritional and fitness goals better when these goals are achievable. Our providers work hard to make sure this happens."

Dr. Siaw added, "We're excited to launch this comprehensive weight management program. By combining access to medical professionals, highly effective weight loss medications, nutritional guidance, and fitness expertise, all within one app, we're empowering individuals to achieve their goals holistically and sustainably."

About Mobile-health Network Solutions Pte Ltd [MaNaDr]

Ranked #41 in the Financial Times 2024 listing of 500 High-growth Asia-Pacific Companies, ManNaDr is the first telehealth provider from the Asia-Pacific region to be listed in the US (Nasdaq). Through its MaNaDr platform app, it offers personalized and reliable medical attention to users worldwide. The platform allows the community of healthcare providers to have a broader reach to users through virtual clinics without any start-up costs and the ability to connect to a global network of peer-to-peer support groups and partners. The range of seamless and hassle-free telehealth solutions includes teleconsultation services, prescription fulfillment and other personalized services such as weight management programs and gender-specific care. For more information, please visit https://manadr.com. For Investor Relations, please visit https://investors.manadr.com.

Considering GLP-1 medications for weight management. Learn more about this option and explore if it's right for you. Visit our website https://manadr.com/weight-management or schedule a convenient teleconsultation with our specialist doctors through the MaNaDr app.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Mobile-health Network Solutions specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Is Poor Sleep During Pregnancy Setting Your Baby Up for Developmental Challenges?September 28, 2024
Can India Save Modern Medicine? The War Against Antimicrobial Resistance Begins HereSeptember 28, 2024
Mpox Clade I: The Deadly Virus India's Fighting to ContainSeptember 28, 2024
Nat Habit Launches debuts its brand campaign ‘Breathe Life into Your Beauty’,September 27, 2024
Twist Teams Up with MedGenome in India to Diagnose Rare DiseasesSeptember 26, 2024
Twist Teams Up with MedGenome in India to Diagnose Rare DiseasesSeptember 26, 2024
What Every Parent Needs to Know About Autism and Pandemic BabiesSeptember 26, 2024
Rush to Judgment? Here’s Why Sleeping on It Leads to Better OutcomesSeptember 26, 2024
Unveiling the Future of Health: Cholera Prevention, Liver Tumor Treatment, and the Truth About Screen TimeSeptember 26, 2024
India Leads the Global War on Synthetic Drugs: A Fight Against Terrorism and TraffickingSeptember 25, 2024
AI bowel cancer test can tell whether patients need chemotherapy September 25, 2024
Exploring Cancer’s Genetic Blueprint: How RAD51C Variants Shape Breast and Ovarian Cancer RiskSeptember 25, 2024
Are Your Medications Safe? The Shocking Truth About India's Failing Drug StandardsSeptember 25, 2024
Fermenta Biotech Limited receives EU GMP Certification for its Dahej Manufacturing Facility, Gujarat, India. September 24, 2024
Is Your Baby at Risk? Black Nose Disease and the Alarming Spread of ChikungunyaSeptember 24, 2024
Women Leading the Charge in Organ Donation—But Where Are the Men?September 24, 2024
Mpox: A New Threat Looms Over India with the Fast-Spreading Clade 1bSeptember 24, 2024
Bhopal Hosts Third State-Level Consultation on Glaucoma PreventionSeptember 23, 2024
From Data to Lifesaving Discoveries: The Portal That’s Redefining Precision OncologySeptember 23, 2024
In the Skies for Life: How the Indian Air Force is Saving Lives and Providing ReliefSeptember 23, 2024